Join our daily newsletter At The Bell to receive exclusive market insights
- Initial data from Patrys’ (PAB) latest preclinical study find its PAT-DX1 candidate significantly reduces pancreatic tumour growths in animal models
- PAT-DX1 reduced the growth of pancreatic tumours by 26 per cent and increased survival rates from 19 to 28 days, the data show
- The study was conducted in the laboratory of Associate Professor Marina Pajic of the Garvan Institute of Medical Research
- Patrys shares are up 2.04 per cent to trade at 5 cents at 1:17 pm AEST
Initial data from Patrys’ (PAB) latest preclinical study have found its PAT-DX1 candidate significantly reduced pancreatic tumour growths in animal models.
The study found a twice-weekly treatment of PAT-DX1 reduced the growth of pancreatic tumours by 26 per cent and increased median survival by 47 per cent, from 19 days to 28 days.
Patrys said the nature of pancreatic cancer tumours made it makes it difficult to develop traditional antibody-based therapeutics for the disease and that its candidate could be a strong contender for future development of deoxymab-based therapies.
Patrys Chief Executive Officer and Managing Director, James Campbell said the findings validated the approach the company had taken with its antibody platform.
“We believe the combination of natural tumour targeting with blocking DNA damage repair, which Patrys’ deoxymabs offers, provides a unique and very powerful approach for tackling difficult-to-treat cancers,” he said.
“On the back of this exciting data, we look forward to continuing our work with Associate Professor Pajic evaluating the potential of both PAT-DX1 and PAT-DX3 as new, potent treatments for pancreatic cancer.”
The study was conducted in the laboratory of Associate Professor Marina Pajic of the Garvan Institute of Medical Research.
Patrys shares were up 2.04 per cent to trade at 5 cents at 12:06 pm AEST.
